Eden Morris should be in kindergarten with his friends but the 5-year-old has been home since the school year started.
Mylan's EpiPen, the life-saving and costly allergy treatment, will soon face a generic rival, a first in more than two decades on the market.
Drugmaker Mylan has started selling a $300 generic version of its emergency allergy treatment EpiPen at half the price of the branded option, the cost of which drew national scorn and attracted Congressional inquiries.
The CEO of the pharmaceutical company that makes the life-saving EpiPen strongly defended the product’s huge price hike on Capitol Hill on Wednesday.
Mylan says it will make available a generic version of its EpiPen, as criticism continued to mount over the price of its injectable medicine.
